Mar. 2017: CellMosaic®, Inc. receives Notice of Allowance from USPTO on reversible oxime photocrosslinking reagent (oxLink™) molecules for studying protein-protein interactions (Patent Application No. 14/965,699). 

Feb. 2017: CellMosaic, Inc. received Notice of Allowance on AqueaTether™ (AqT™) molecules from the Chinese Intellectual Property Office (Chinese Patent Application No. 201280034231.3)

Feb. 2017: Received the registration certificate from USPTO for trademark "CELLMOSAIC" (registration no. 5,105,195, Int. Cl.: 1, 42).

Nov. 2016: CellMosaic received Notice of Allowance from USPTO on NeIon™ Molecules (Application No. 15/136,920)

Aug. 2016: CellMosaic received Notice of Allowance from USPTO for AqueaTether™ Molecules (Application No. 14/156,224).

Apr. 2016: CellMosaic received the 2015 Joseph R. Carter Innovation Award

Apr. 2016: Received Notice of Allowance from USPTO for NeIon™ Technologies (Application No. 14/779,805)

Dec. 2015: Relocate the lab space from Worcester to Woburn, MA

Mar. 2015: Awarded a Breast Cancer Research Program Breakthrough Award from Department of Defense (DOD) Office of CDMRP 

Oct. 2014: Received Notice of Allowance from USPTO for AqueaTether™ Molecules (Application No. US14/210.121)

Dec. 2013: CellMosaic was converted from a MA Limited Liability Company to a Delaware C corporation

Oct. 2013: Signed a collaboration research agreement with NCI to co-develop AqT™ based antibody drug conjugates

Sept. 2012: Awarded Phase I SBIR grant from the NIGMS/NIH

Nov. 2010: Voted one of "Five startups to watch" in New England by Mass. High. Tech.

Oct. 2008: Registered the company as MA LLC and established lab space in Worcester, MA